36.6 F
New York
Thursday, April 22, 2021

AstraZeneca [NYSE: AZN] And Sanofi’s [NASDAQ: SNY] Nirsevimab Shows Positive Result In Phase 2 Trial

Must read

Palantir [NYSE: PLTR] Recognized as a Crown Commercial Service supplier

Palantir Technologies Inc. has gained recognition as a supplier on the Crown Commercial Service (CCS) Back Office Software (BOS) RM6194 Framework. This award...

Trevena [NASDAQ: TRVN] Soar on Selection of TRV027in Global COVID-19 Trial

Shares of Trevena, Inc. skyrocketed more than 5 percent during the pre-market trading session of Wednesday. The strong performance of the firm indicated...

InfuSystem Announces Acquisition of OB Healthcare Corporation

InfuSystem Holdings Inc. disclosed Wednesday that it has bought OB Healthcare Corporation. As per the acquisition agreement, the firm has purchased the operating...

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

AstraZeneca PLC [NYSE: AZN] and development partner Sanofi’s [NASDAQ: SNY] nirsevimab has shown a promising result in Phase 2 clinical trial, companies disclosed today. Both Sanofi and AstraZeneca have signed an agreement in March 2017 for the development and commercialization of Nirsevimab.

The current Phase 2 study result has shown a significant reduction in Respiratory Syncytial Virus (RSV) infections which required medical care in the healthy premature infant. Nirsevimab has decreased the infections by 70% and the need for medical care by 78%.

Respiratory Syncytial Virus (RSV) is a lower respiratory tract infection. RSV is a contagious virus that infects the respiratory tract and the most common cause of pneumonia and bronchiolitis. Nirsevimab which is co-developed by Sanofi and AstraZeneca reduced the infections caused by RSV in infants who are experiencing their first RSV season.

Shares of AstraZeneca traded up 0.57% during the trading of Wednesday. Its closing price is $56.64. AZN has a 52-weeks low and high range of $36.15-$64.94, respectively. AZN has a day high range of $57.05 and a day low range of $56.09.

It had a trading volume of roughly 5.04 million as compared to the average volume of 7.14 million. Continuing to look at its profitability, its return on assets (ROA) is 2.50%, return on equity (ROE) is 12.30%, and return on investment (ROI) is 8.30%.

AZN has a Gross Margin of 79.60%, a Profit Margin of 6.00%, and an Operating Margin of 12.10%. Turning our focus on liquidity, its quick ratio is 0.60 and the current ratio is 0.80.

On the other hand, Sanofi’s shares have exhibited a change of 1.95% at $52.84 during the trading session on Wednesday. Its return on investment (ROI) is 3.50%. SNY has a Gross Margin of 68.00%, a Profit Margin of 13.60%, and an Operating Margin of 16.20%.

In the past 52-weeks of trading, its stocks fluctuated between the low of $37.62 and a high of $55.00. SNY has moved up 40.46% from 52-weeks of low range and moved down -3.93% from the 52-weeks of high range.

Phase 2b trial of Nirsevimab fulfilled the primary and secondary endpoints. Nirsevimab gained a statistically significant 70.1% (95% CI: 52.3%-81.2%) reduction of medically attended RSV LRTI contrasted to placebo through 150 days post-dose on the primary endpoint.

On the secondary endpoint, nirsevimab achieved a 78.4% (95% CI: 51.9%-90.3%) relative reduction in the need for medical care due to RSV LRTI compared to placebo through 150 days post-dose.

More articles

Latest article

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...